Testosterone Science

Heart and Cardiovascular Safety

The Unseen Risks: Rising Testosterone Use Among Youth Without Medical Indication

Specific Claim Evaluated

TRAVERSE studied older men with cardiovascular disease, and its findings cannot be applied to younger, healthy individuals using testosterone without medical indication.

Primary Research Supporting or Contradicting the Claim

TRAVERSE enrolled men aged 45 to 80 years with hypogonadism and preexisting or high cardiovascular risk (Lincoff et al., 2023). Former users of anabolic-androgenic steroids can have persistent low testosterone years after stopping (Rasmussen et al., 2016).

Corrected Evidence-Based Interpretation

The article is correct.

Rationale for Grade

The authors correctly limit the trial population, describe suppression of the hypothalamic-pituitary-gonadal axis and recommend harm reduction monitoring. No claim overstates the evidence.

References

  1. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
    Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events"
  2. Rasmussen JJ, Selmer C, Østergren PB, Pedersen KB, Schou M, Gustafsson F, Faber J, Juul A, Kistorp C. Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case-control study. PLoS One. 2016;11(8):e0161208. PMID
    Supporting excerpt: "Former AAS abusers exhibited significantly lower plasma testosterone levels"

Post a Comment

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.